Derivation of an occupational exposure limit for benzene using epidemiological study quality assessment tools.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
01 Nov 2020
Historique:
received: 28 02 2020
revised: 20 05 2020
accepted: 28 05 2020
pubmed: 5 6 2020
medline: 5 11 2020
entrez: 5 6 2020
Statut: ppublish

Résumé

This paper derives an occupational exposure limit for benzene using quality assessed data. Seventy-seven genotoxicity and 36 haematotoxicity studies in workers were scored for study quality with an adapted tool based on that of Vlaanderen et al., 2008 (Environ Health. Perspect. 116 1700-5). These endpoints were selected as they are the most sensitive and relevant to the proposed mode of action (MOA) and protecting against these will protect against benzene carcinogenicity. Lowest and No- Adverse Effect Concentrations (LOAECs and NOAECs) were derived from the highest quality studies (i.e. those ranked in the top tertile or top half) and further assessed as being "more certain" or "less certain". Several sensitivity analyses were conducted to assess whether alternative "high quality" constructs affected conclusions. The lowest haematotoxicity LOAECs showed effects near 2 ppm (8 h TWA), and no effects at 0.59 ppm. For genotoxicity, studies also showed effects near 2 ppm and showed no effects at about 0.69 ppm. Several sensitivity analyses supported these observations. These data define a benzene LOAEC of 2 ppm (8 h TWA) and a NOAEC of 0.5 ppm (8 h TWA). Allowing for possible subclinical effects in bone marrow not apparent in studies of peripheral blood endpoints, an OEL of 0.25 ppm (8 h TWA) is proposed.

Identifiants

pubmed: 32497562
pii: S0378-4274(20)30226-5
doi: 10.1016/j.toxlet.2020.05.036
pii:
doi:

Substances chimiques

Air Pollutants, Occupational 0
Mutagens 0
Benzene J64922108F

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-144

Informations de copyright

Copyright © 2020 Lower Olefins and Aromatics REACH Consortium. Published by Elsevier B.V. All rights reserved.

Auteurs

A Robert Schnatter (AR)

EpiSolutions LLC, Melbourne, FL, USA.

Martijn Rooseboom (M)

Shell International B.V. The Hague, the Netherlands.

Neslihan Aygun Kocabas (NA)

SABIC Europe B.V. Sittard, the Netherlands.

Colin M North (CM)

ExxonMobil Biomedical Sciences, Inc, Annandale, NJ, USA.

Abigail Dalzell (A)

Penman Consulting Limited, Wantage, UK.

Johannes Twisk (J)

Dow Chemical International Pvt. Ltd, Terneuzen, the Netherlands.

Frank Faulhammer (F)

BASF SE, Ludwigshafen, Germany.

Erik Rushton (E)

Basell Service Company B.V., Rotterdam, the Netherlands.

Peter J Boogaard (PJ)

Shell International B.V. The Hague, the Netherlands.

Viktorija Ostapenkaite (V)

Penman Consulting Limited, Wantage, UK.

Stephen D Williams (SD)

Penman Consulting Limited, Wantage, UK. Electronic address: benzeneoel@penmanconsulting.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH